novel
pneumoniaassoci
respiratori
syndrom
name
coronaviru
caus
broken
wuhan
china
end
unfortun
specif
antivir
agent
vaccin
avail
treat
infect
also
inform
regard
immunolog
sever
pneumoniaassoci
respiratori
syndrom
spread
rapidli
wuhan
china
end
novel
coronaviru
offici
name
sever
acut
respiratori
syndrom
coronaviru
identifi
culprit
pathogen
also
offici
name
coronaviru
infect
list
outbreak
public
health
emerg
intern
concern
viru
far
caus
confirm
case
death
china
accord
rapidli
spread
countri
worldwid
includ
italia
iran
japan
unit
state
accord
transcriptom
sequenc
share
homolog
sarscov
homolog
bat
coronaviru
wholegenom
level
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
respect
accord
pairwis
protein
sequenc
analysi
seven
conserv
nonstructur
protein
domain
envelop
positivesens
rna
viru
belong
famili
coronavirus
includ
sarscov
merscov
current
specif
antivir
agent
vaccin
avail
treat
infect
clinic
treatment
patient
primarili
support
symptomat
treatment
although
sever
potenti
therapeut
target
repurpos
exist
antivir
agent
develop
effect
intervent
novel
coronaviru
toxicolog
clinic
trial
requir
potenti
use
clinic
accord
patholog
report
shown
mainli
caus
inflammatori
respons
lung
sever
studi
show
patient
develop
lymphopenia
rise
proinflammatori
cytokin
sever
case
inflamm
trigger
innat
adapt
immun
cell
detect
infect
innat
cell
provid
first
line
defens
pathogen
howev
innat
cell
respond
infect
remain
unclear
among
innat
immun
cell
cell
prolifer
rapidli
respond
pathogen
induc
apoptosi
mediat
antigen
present
immun
regul
healthi
adult
human
cell
repres
total
circul
lymphocyt
predomin
display
doubl
neg
phenotyp
howev
case
fraction
cell
express
either
cell
recogn
classic
peptid
antigen
tcr
nonmhc
restrict
respond
pathogenassoci
molecular
pattern
produc
cytokin
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
absenc
tcr
ligand
mani
infect
number
cell
increas
local
system
day
postinfect
studi
found
ratio
cell
among
total
lymphocyt
lung
significantli
increas
mice
infect
influenza
viru
three
day
post
infect
observ
suggest
cell
play
import
role
host
immun
respons
acut
hiv
infect
previou
studi
show
surfac
express
activ
marker
significantli
increas
cell
wherea
variou
virus
may
differ
effect
pattern
cell
activ
demonstr
cell
behav
upon
infect
analyz
pbmc
sampl
patient
focus
character
cell
phenotyp
show
upon
infect
percentag
cell
peripher
blood
isol
patient
drastic
decreas
compar
healthi
donor
figur
although
acut
earli
stage
viral
percentag
cell
increas
observ
decreas
cell
symptomat
patient
might
explain
variou
type
viru
impact
cell
differ
way
like
cell
respons
includ
prolifer
cellular
depend
specif
type
viral
infect
also
possibl
patient
studi
show
mild
symptom
besid
fever
oppos
seriou
ill
featur
pneumonia
interestingli
found
comparison
hd
group
percentag
cell
within
cell
popul
increas
dramat
remain
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
unchang
patient
b
c
increas
cell
indic
respons
infect
particular
subset
cell
may
play
role
antigen
present
facilit
activ
adapt
immun
cell
demonstr
differ
model
data
also
suggest
subset
immun
cell
could
immedi
respond
viral
infect
similar
innat
immun
cell
macrophag
dendrit
cell
provid
first
line
immun
defens
therefor
cell
may
act
bridg
innat
adapt
immun
respons
infect
covid
patient
observ
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
studi
approv
research
ethic
commiss
eighth
hospit
xian
subject
sign
inform
consent
form
upon
admiss
hospit
studi
case
taken
eighth
hospit
xian
xian
shaanxi
provinc
peopl
republ
china
studi
includ
healthi
control
patient
februari
march
patient
enrol
confirm
infect
use
pcr
test
throat
swab
specimen
student
test
perform
two
group
analysi
use
graphpad
prism
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
softwar
stand
p
p
respect
declar
compet
interest
lei
lei
xiaofeng
yang
xingzh
zhang
dan
zhang
wrote
manuscript
xiaofang
yang
tongxin
dai
rui
guo
collect
sampl
inform
patient
jinsong
hu
analyz
fac
data
xiaobo
zhou
lin
shi
yanbin
cheng
respons
discuss
data
baojun
zhang
gener
idea
design
experi
analyz
data
wrote
manuscript
author
agre
account
part
work
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
patient
healthi
donor
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
